TREM2-mediated microglial phagocytosis of inhibitory synapses contributes to prolonged FS-induced epileptogenesis

Xiaoqian Wang1, Hua Zhou1, Yujie Zhai1

  • 1School of Pharmaceutical Sciences, Binzhou Medical University, Yantai, China.

Cell Death Discovery
|April 11, 2026
PubMed

Insights

Febrile seizures (FS) can lead to epilepsy. Reducing triggering receptor expressed on myeloid cell 2 (TREM2) levels in microglia may prevent this by decreasing synapse phagocytosis, offering a new epilepsy treatment target.

Area of Science:

  • Neuroscience
  • Immunology
  • Epilepsy Research

Background:

  • Febrile seizures (FS) are common in childhood and a significant cause of epilepsy.
  • Current antiepileptic drugs often fail to prevent epileptogenesis and can worsen it.
  • The role of Triggering Receptor Expressed on Myeloid Cell 2 (TREM2) in FS-induced epilepsy is not well understood.

Purpose of the Study:

  • To investigate the role of TREM2-mediated microglial phagocytosis in prolonged FS-induced epileptogenesis.
  • To explore potential therapeutic strategies targeting TREM2 signaling.

Main Methods:

  • Established a rat model of juvenile prolonged FS.
  • Analyzed molecular changes, microglial activation, and synaptic phagocytosis.
  • Administered a CD33 agonist (GM1) and utilized TREM2 knockdown and PtdSer blocking strategies.

Main Results:

  • Prolonged FS increased TREM2 levels, excessive microglial phagocytosis of inhibitory synapses, and epileptic susceptibility.
  • CD33 activation and TREM2 knockdown reduced microglial phagocytosis and epileptic susceptibility.
  • Blocking TREM2-ligand interaction (PtdSer) exacerbated microglial activation and epilepsy.

Conclusions:

  • Reducing TREM2 levels can inhibit FS-induced epileptogenesis by modulating microglial phagocytosis of inhibitory synapses.
  • Targeting TREM2 offers a potential therapeutic avenue for preventing epilepsy following febrile seizures.

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.8K